. 2021 Aug 2;125(8):1089–1099. doi: 10.1038/s41416-021-01512-9

Table 1.

Eligibility criteria, recruitment and informed consent processes.

Protocol domain	Study information
Eligibility criteria	• Eligible oncologists: Primary oncologists providing medical care to solid tumour patients at the institution. • Other eligible providers: Non-primary oncologist healthcare professionals (e.g. fellows, students, nurses, psychosocial providers) who attended a recorded disease re-evaluation conversation for an enrolled study patients (participation limited to attendance during recording). • Eligible patients: Aged 0–30 years, solid tumour diagnosis with survival of ≤50% estimated by their primary oncologist, projected to have ≥2 future timepoints of disease re-evaluations. • Eligible parents/guardians: Legal caregiver of eligible patient, aged ≥18 years, English language proficiency, planned to accompany patient to medical visits. • Others: Family or friends of an enrolled patient–parent dyad who attended a recorded disease re-evaluation conversation (participation limited to attendance during recording).
Recruitment and informed consent	• The Principal Investigator (PI) sent emails to a convenience sample of all eligible primary oncologists at the study site to introduce the study and determine interest in participating; once interest was expressed, the PI met one-on-one with oncologists to describe the study and complete the informed consent process. No oncologists declined participation. • Eligible non-primary oncologist healthcare professionals were introduced to the study by the PI or research team member during clinic or office time preceding a scheduled recording. The study was described and informed consent obtained. • Eligible patient/parent dyads were identified by the research team through review of outpatient clinic schedules and institutional trial lists. The PI reviewed all identified patients to determine those with overall survival reasonably estimated at 50% or less. A member of the research team then asked the patient’s primary oncologist to confirm prognosis by asking: “In your clinical judgement, would you estimate [patient name]’s overall survival at 50% or less?” Permission to approach eligible dyads was requested from the primary oncologist. Patient–parent dyads were then approached by a member of the research team during a clinic visit to determine interest in participation. If interested, the study was described in detail. Dyadic enrollment required agreement from both patient and parent. Patients aged ≥12 years provided assent, and patients aged ≥18 years and parents provided consent. • Eligible family/friends were introduced to the study by the PI or research team member prior to recording the visit, and verbal consent was obtained.

Protocol domain

Study information

Eligibility criteria

• Eligible oncologists: Primary oncologists providing medical care to solid tumour patients at the institution.

• Other eligible providers: Non-primary oncologist healthcare professionals (e.g. fellows, students, nurses, psychosocial providers) who attended a recorded disease re-evaluation conversation for an enrolled study patients (participation limited to attendance during recording).

• Eligible patients: Aged 0–30 years, solid tumour diagnosis with survival of ≤50% estimated by their primary oncologist, projected to have ≥2 future timepoints of disease re-evaluations.

• Eligible parents/guardians: Legal caregiver of eligible patient, aged ≥18 years, English language proficiency, planned to accompany patient to medical visits.

• Others: Family or friends of an enrolled patient–parent dyad who attended a recorded disease re-evaluation conversation (participation limited to attendance during recording).

Recruitment and informed consent

• The Principal Investigator (PI) sent emails to a convenience sample of all eligible primary oncologists at the study site to introduce the study and determine interest in participating; once interest was expressed, the PI met one-on-one with oncologists to describe the study and complete the informed consent process. No oncologists declined participation.

• Eligible non-primary oncologist healthcare professionals were introduced to the study by the PI or research team member during clinic or office time preceding a scheduled recording. The study was described and informed consent obtained.

• Eligible patient/parent dyads were identified by the research team through review of outpatient clinic schedules and institutional trial lists. The PI reviewed all identified patients to determine those with overall survival reasonably estimated at 50% or less. A member of the research team then asked the patient’s primary oncologist to confirm prognosis by asking: “In your clinical judgement, would you estimate [patient name]’s overall survival at 50% or less?” Permission to approach eligible dyads was requested from the primary oncologist. Patient–parent dyads were then approached by a member of the research team during a clinic visit to determine interest in participation. If interested, the study was described in detail. Dyadic enrollment required agreement from both patient and parent. Patients aged ≥12 years provided assent, and patients aged ≥18 years and parents provided consent.

• Eligible family/friends were introduced to the study by the PI or research team member prior to recording the visit, and verbal consent was obtained.